All Patents articles
View all stories with this category.
-
-
Opinion
Rewards based on priority drive unnecessary competition
The story of Crispr illustrates how a focus on patents and publications can cause good people to act in unsavoury ways
-
Business
Patent applications listing AI as an inventor run into legal problems
Artificial intelligence is increasingly being used to find new chemical compounds and repurpose drugs, but should laws be updated to protect the intellectual property of such discoveries?
-
Business
This little Crispr went to market
Gene editing technology heading towards commercial reality in pharmaceuticals, food and organ transplant
-
Opinion
When should employees share profits from inventions?
Glucose monitor inventor wins £2m payout from Unilever after claiming his work provided ’outstanding benefit’
-
News
Patient and research groups condemn draft bill allowing human gene patenting in US
A measure floated by Congress could hinder research and access to gene tests and raise their costs
-
Research
Patent-busting AI tool navigates around protected drug pathways
Organic retrosynthesis software can identify key bonds involved in patented reactions to find alternative pathways
-
Opinion
Pushing the limits of patent protection
Some methods of extending exclusivity rights raise legal and ethical questions
-
Opinion
Has Crispr’s patent battle run its course?
As the originators duke it out in court, their patents are becoming increasingly irrelevant
-
Business
‘No deal’ Brexit guidance fails to reassure UK chemical industry
UK government issues guidance on chemical regulation and patent law if the UK leaves the EU without agreement
-
Sponsored
The dark side of chemical patents
Unloved, ignored and misunderstood but could all that change?
-
Sponsored
A guide to searching and using Markush structures
Chemical patents are often very long and difficult to read. Markush searching can enable you to easily categorise and filter the information you need, giving you the insights that a paper sometimes cannot.
-
-
Business
Pharmaceuticals roundup 2017
Political influence has strongly shaped industry activity in the past year
-
Business
Federal court quashes Allergan eye drop patents
Ruling negates company’s deal with Mohawk tribe to avoid patent board review
-
Business
US government urged to exercise drug patent rights
Campaign group says withdrawing Biogen’s license to government patents, or re-licensing them to other companies, could lower MS drug prices
-
Business
Allergan sidesteps patent review with tribal deal
Native Americans agree to use sovereign immunity to protect intellectual property from double challenge
-
Business
US court denies Amgen appeal over Pfizer biosimilar
Amgen has lost its bid to compel Pfizer to divulge information about its version of anaemia drug Epogen
-
Business
Broad Institute backs central Crispr patent licensing platform
Key players submit 22 patents to pool, and urge other holders to create a one-stop shop for licensing deals
-
Business
Lilly wins chemotherapy patent appeal
Firm also settles with generic manufacturers of erectile dysfunction drug Cialis
